UBS raised the firm’s price target on Guardant Health (GH) to $70 from $65 and keeps a Buy rating on the shares. Guardant Health reported a quarterly beat, with guidance raised amid better volume and average selling price, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GH:
- Guardant Health price target raised to $65 from $60 at BTIG
- Guardant Health price target raised to $65 from $60 at Canaccord
- Guardant Health’s Strong Growth Potential and Upward Trajectory Justifies Buy Rating
- Guardant Health: Strong Financial Performance and Growth Potential Justify Buy Rating
- Guardant Health: Strong Financial Performance and Strategic Positioning Drive Buy Rating